Lupus Science & Medicine

International development of a lupus-specific instrument to assess cognitive symptoms in patients with SLE: Lupus Brain Fog Severity Scale (LBFSS) study

Introduction Cognitive symptoms such as ‘brain fog’ are frequent and disabling in patients with SLE. We aimed to develop and ...
Lupus Science & Medicine

Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study

Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist ...
Lupus Science & Medicine

Qualitative interview study in patients with SLE to assess patient perception of fatigue and skin-related symptoms

Objective SLE is a chronic autoimmune disorder with a range of symptoms. While these are broadly reported in the literature, ...
lupus.bmj

Remission and low disease activity state in childhood-onset systemic lupus erythematosus: differential impact on damage accrual in a Latin American cohort (GLADEL)

Objective To examine the impact of different disease activity states (DAS) on outcomes in a longitudinal inception childhood-onset SLE cohort. Materials and methods Three DAS were included—remission: ...
Lupus Science & Medicine

Are RAS inhibitors necessary during intensive immunosuppression for lupus nephritis? Real-world evidence from the STAR cohort

Objective While guidelines advocate renin-angiotensin system inhibitors (RASi) for renoprotection in lupus nephritis (LN), ...
Lupus Science & Medicine

Increasing the utilisation of hydroxychloroquine blood level testing in lupus: a quality improvement project

Objective Hydroxychloroquine (HCQ) is a cornerstone therapy for SLE, reducing flares, organ damage and mortality. However, ...
lupus.bmj

Comparison of BAFF and type I IFN activity in blood and placenta in SLE and healthy pregnancies

Objective To examine B cell-activating factor (BAFF) and type I interferon (IFN) activity at the transcriptional and protein levels in blood and placental tissue in SLE compared with healthy ...
lupus.bmj

PO:02:027 Disease activity modulation and pharmacodynamic biomarkers observed upon afimetoran treatment in patients with cutaneous lupus erythematosus

Objectives Cutaneous lupus erythematosus (CLE) is a chronic inflammatory skin condition with no approved targeted treatments. Afimetoran – a first-in-class, once daily oral, selective, equipotent, ...
lupus.bmj

Combining mepacrine with hydroxychloroquine-based therapy in active systemic lupus erythematosus: an observational study of 106 patients from the Lupus-Cruces cohort

Objective To evaluate the efficacy of mepacrine (MC) as an add-on therapy in patients with SLE unresponsive to hydroxychloroquine (HCQ)-containing regimens at 6 months after MC introduction. Methods ...
lupus.bmj

Development and validation of nomograms for predicting activity index and tubulointerstitial lesions in lupus nephritis: a multicentre study

Objective Lupus nephritis (LN) is a prevalent renal manifestation in patients with SLE, with kidney biopsy remaining the gold standard for evaluating disease activity. However, the invasive nature of ...
lupus.bmj

Amelioration of renal injury by Qihuang Jianpi Zishen Granules in lupus mice is correlated with AMPK/ULK1-dependent modulation of macrophage polarisation

Objective To investigate the effects of Qihuang Jianpi Zishen Granules (QJZG) on renal injury in SLE mice, focusing on macrophage M1/M2 polarisation mediated by the AMPK/ULK1 signalling pathway.
lupus.bmj

11 Managing haematologic manifestations in SLE

Haematologic involvement in patients with systemic lupus erythematosus (SLE) is very common. The principal cytopenias in lupus result in anaemia, white cell deficits and thrombocytopenia. Anaemia may ...